Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype

Blood

Volumn 96, Issue 9, 2000, Pages 2993-3000

  Suzuki, R ^a   Kagami, Y ^a   Takeuchi, K ^a   Kami, M ^a   Okamoto, M ^a   Ichinohasama, R ^a   Mori, N ^a   Kojima, M ^a   Yoshino, T ^a   Yamabe, H ^a   Shiota, M ^a   Mori, S ^a   Ogura, M ^a   Hamajima, N ^a   Seto, M ^a   Suchi, T ^a   Morishima, Y ^a   Nakamura, S ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CD56 ANTIGEN; LACTATE DEHYDROGENASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CHILD; CHROMOSOME TRANSLOCATION 2; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NULL CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD56; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; LYMPHOMA, LARGE-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-TYROSINE KINASES; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 0034329288     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
2. CD30 expression in non-Hodgkin's lymphoma
3. Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese
4. Updated Kiel classification for lymphomas
5. Histopathology and immunohistochemistry of peripheral T cell lymphomas: A proposal for their classification
6. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
7. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997
8. Malignant histiocytosis: A specific t(2;5)(p23;q35) translocation? Review of the literature
9. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene
10. A novel translocation t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis
11. Fusion of a kinase gene, ALK, to a molecular protein gene, NPM, in non-Hodgkin's lymphoma
12. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
13. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry
14. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
15. ALK expression defines a distinct group of T/null lymphomas ('ALK lymphomas') with a wide morphological spectrum
16. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease
17. Absence of the t(2;5) in Hodgkin's disease
18. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease
19. + anaplastic large cell lymphomas and in other non-Hodgkin's lymphomas of T-cell phenotype
20. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions
21. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining
22. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliterative disorders and Hodgkin's disease
23. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis
24. Anaplastic large cell lymphomas expressing the novel chimeric protein p80(NPM/ALK): A distinct clinicopathologic entity
25. + lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin
26. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma
27. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
28. Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression
29. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
30. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
31. + lymphoma: Clinico-pathological findings and outcome
32. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
33. Characterization of an antigen expressed by human natural killer cells
34. The relationship of CD16(Leu-11) and Leu-19(NKH-1) antigen expression of human peripheral blood NK cells and cytotoxic T lymphocytes
35. Classification of natural killer (NK) cell and NK-like T-cell malignancies
36. Malignancies of natural killer (NK) cell precursor: Myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia
37. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22)
38. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
39. Nodal cytotoxic lymphoma spectrum: A clinicopathologic study of 66 patients
40. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
41. Inconsistent association of Epstein-Barr virus with CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract
42. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
43. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
44. + myeloid/natural killer cell precursor acute leukemia: A distinct hematolymphoid disease entity
45. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract
46. Aggressive natural killer cell leukemia in an adult and establishment of an NK cell line
47. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas
48. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56)
49. Expression N-CAM (CD56) on acute leukemia cells: Relationship with disease characteristics and outcome
50. S100-positive, T-cell chronic lymphoproliferative disease: An aggressive disorder of an uncommon T-cell subset
51. Natural killer-like T-cell lymphomas: Aggressive lymphomas of T-large granular lymphocytes
52. Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic γδ T-cell origin
53. Microvillous lymphomas are B-cell neoplasms that frequently express CD56
54. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: A rare variant with a propensity for unusual sites of involvement
55. Diffuse large B cell lymphoma expressing the natural killer cell marker CD56
56. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)
57. Phenotypic difference of normal plasma cells from mature myeloma cells
58. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma
59. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression
60. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics
61. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): Correlation with morphology, immunophenotype, ultrastructure, and clinical features
62. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin
63. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules
64. Clinicopathological correlates of CD56 expression in multiple myeloma: A unique entity?
65. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications
66. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo
67. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma)
68. Anaplastic large-call lymphoma: Clinical and prognostic evaluation of 90 adult patients
69. A novel variant translocation t(2;13) (p23;q34) in Ki-1 large cell anaplastic lymphoma
70. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
71. The cryptic inv(2) (p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma
72. A new variant chromosomal translocation t(2;2)(p23;q23) in CD30+/Ki-1+ anaplastic large cell lymphoma
73. T(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma
74. A new fusion gene, TPM3-ALK, in anaplastic large-cell lymphoma created by a (1;2) (q25;p23) translocation
75. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
76. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
77. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
78. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
79. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
80. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood
81. + anaplastic large cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology
82. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome